A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial

Andre Lamy, Lars Ryden, Wesley Tong, Fei Yuan, John W. Eikelboom, Unknown

Open source

DOI: 10.1080/14017431.2026.2728343
Published: 2026-09-17
Container: Scandinavian Cardiovascular Journal
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14017431.2026.2728343,
  title = {A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial},
  author = {Andre Lamy and Lars Ryden and Wesley Tong and Fei Yuan and John W. Eikelboom and Unknown},
  year = {2026},
  journal = {Scandinavian Cardiovascular Journal},
  doi = {10.1080/14017431.2026.2728343},
  url = {https://doi.org/10.1080/14017431.2026.2728343}
}

RIS

TY  - JOUR
TI  - A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial
AU  - Andre Lamy
AU  - Lars Ryden
AU  - Wesley Tong
AU  - Fei Yuan
AU  - John W. Eikelboom
AU  - Unknown
PY  - 2026
JO  - Scandinavian Cardiovascular Journal
DO  - 10.1080/14017431.2026.2728343
UR  - https://doi.org/10.1080/14017431.2026.2728343
ER  -

APA

Lamy, A., Ryden, L., Tong, W., Yuan, F., Eikelboom, J. W., & Unknown (2026). A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial. Scandinavian Cardiovascular Journal. https://doi.org/10.1080/14017431.2026.2728343

Source records

crossref · retrieved 2026-09-25T14:59:57.889Z